Ferroptosis increases obesity: Crosstalk between adipocytes and the neuroimmune system

Sen Zhang, Zhiyuan Sun, Xing Jiang, Zhimin Lu, Ling Ding, Chengzhi Li, Xuewen Tian* and Qinglu Wang*
College of Sport and Health, Shandong Sport University, Jinan, Shandong, China

Ferroptosis requires not only the accumulation of iron ions, but also changes in many ferroptosis-related regulators, including a decrease in GPX4 and inhibition of SLC7A11 for classical ferroptosis, a deletion of FSP1 or GCH1. Surprisingly, adipose tissue (AT) in the obesity conditions is also accompanied by iron buildup, decreased GSH, and increased ROS. On the neurological side, the pro-inflammatory factor released by AT may have first caused ferroptosis in the vagus nerve by inhibiting the NRF2-GPX4 pathway, resulting in disorders of the autonomic nervous system. On the immune side, obesity may cause M2 macrophages ferroptosis due to damage to iron-rich ATMs (MFe hi) and antioxidant ATMs (Mox), and lead to Treg cells ferroptosis through reductions in NRF2, GPX4, and GCH1 levels. At the same time, the reduction in GPX4 may also trigger the ferroptosis of B1 cells. In addition, some studies have also found the role of GPX4 in neutrophil autophagy, which is also worth pondering whether there is a connection with ferroptosis. In conclusion, this review summarizes the associations between neuroimmune regulation associated with obesity and ferroptosis, and on the basis of this, highlights their potential molecular mechanisms, proposing that ferroptosis in one or more cells in a multicellular tissue changes the fate of that tissue.

KEYWORDS
ferroptosis pathway, obesity, neurological dysfunction, inflammatory response, metabolic disorders

Introduction
Iron metabolism

Iron, which has the highest content of all essential trace elements in the human body, plays a critical role as a biologically essential component of every living organism (1), which is closely related to the development of the human body and the occurrence and development of diseases. Thus, a constant balance requires to be maintained between
iron uptake, transport, storage, and usage to maintain iron homeostasis (2). Iron homeostasis involves the action of multiple cell types, including red blood cells, intestinal cells, hepatocytes, and macrophages (3). When the iron steady state is broken, its basic chemical properties lay the foundation for potential toxicity via the production of reactive oxygen species (ROS), including hydrogen peroxide (H$_2$O$_2$), hydroxyl radicals (·HO), superoxide anions (O$_2^-$), and other reaction intermediates with free radical properties (4, 5). During ATP production in mitochondria, some of the oxygen consumption will be reduced through the monovalent route (5), resulting in the production of the above reactive intermediates. Moreover, because of its redox properties, iron can just have a “Fenton reaction” with H$_2$O$_2$ in it, thereby generating extremely reactive ·HO. Furthermore, when ROS exceeds a certain threshold, it leads to oxidative stress (6, 7); therefore, too much iron can negatively impact the body. Increasing studies have proved that iron overload is the key cause of ferroptosis in cells, and the area of occurrence in the human body is extremely extensive (8). Additionally, long-term intake of a high-fat diet can lead to iron accumulation, which may exacerbate the mechanism of onset (9). The diseases associated with ferroptosis include neurodegenerative diseases (such as Alzheimer’s disease and Parkinson’s disease), ischemic reperfusion damage to the heart, brain, lungs, and kidneys, and stomach cancer and breast cancer (10–17).

Mechanisms governing ferroptosis

Ferroptosis, unlike apoptosis, autophagy, and cell necrosis, is a regulatory form of cell death that depends on iron and ROS. This form of death was first reported in Brent R Stockwell’s lab in 2012 (18). The mechanism of ferroptosis involves the highly expressed polyunsaturated fatty acids (PUFAs; such as docosahexaenoic acid and arachidonic acid) on the cell membrane, which are driven by acyl-Coenzyme A synthase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3). As a result, these PUFAs are modified to long chains and re-esterify them into phospholipids that infiltrate into lipids and membranes, forming PUFA-PL with carbon-centered phospholipid radicals (PLOO•) (19–22) (Figure 1A). Subsequently, non-enzymatic self-oxidation occurs with molecular oxygen under the catalysis of the Fenton reaction, which is initiated by iron and H$_2$O$_2$ to produce phospholipid peroxy radicals (PLOOH), which are generated by removing hydrogen from another PUFA to
generate PLOOH (6, 22). Simultaneously, with the participation of iron, PUFA-PL undergoes an enzymatic reaction to generate PLOOH under the direct or indirect catalysis of lipoxigenase (LOX) and cytochrome P450 oxidoreductase (POR) (23, 24) (Figure 1A). When PLOOH is not rapidly neutralized as an LOX and cytochrome P450 oxidoreductase (POR) (23, 24) PLOOH under the direct or indirect catalysis of lipoxygenase iron, PUFA-PL undergoes an enzymatic reaction to generate morphology, genetics, and biochemistry. Morphologically, the main inhibitory pathway of iron apoptosis, the system xc− is inhibited, the upstream regulator system x− is inhibited, and the cystine transport pathway is blocked, resulting in a reduction in cystine transfer and cysteine reduced by NADPH (8, 25). As the rate-limiting precursor of glutathione (GSH), cysteine can cause a decrease in the activity of GPX4 and a large accumulation of lipid peroxides when deficient, which eventually leads to ferroptosis.

Main regulator of ferroptosis

**GPX4**

Since Scott J. Dixon first discovered and named ferroptosis, the critical role of GPX4 in the inhibition of ferroptosis in his study has received widespread attention, mainly in the antioxidant axis system \(x_{c} \cdot \text{GSH} - \text{GPX4} \) (18). Due to GPX4's excellent antioxidant capacity, it can detoxify intracellular lipid and cholesterol hydroperoxide product build-up by using GSH as a cofactor (32, 33). Furthermore, increasing studies have proven that GPX4 is the core regulator of ferroptosis (8). Indeed, as long as part of the GPX4 activity is maintained, cells lacking other selenoproteins can still survive and proliferate. However, the loss of GPX4 leads to the lethality of early embryos in mice. For example, in CAMKIIalpha-driven GPX4 knockout (KO) mice, mitochondrial dysfunction and ferroptosis due to chelated lipid peroxidation caused mice to display spinal motor neuron degeneration, paralysis, and death within 8 days of knockout (34), suggesting that cellular ferroptosis can be affected by regulating GPX4. GPX4 is also regulated in terms of activity and stability levels. GSH, as a cofactor is a direct factor affecting GPX4 (35), is derived from the tripeptides of glutamic acid, glycine, and cysteine, and is the most abundant reducing agent in mammalian cells (36). Notably, independent of the antioxidant properties of GSH, it also can regulate the NO steady state, forming nitrosyl mercaptans (37). In summary, GSH is important for the physiological occurrence of iron-sulfur clusters, preventing oxidative damage, and directly regulating glucose homeostasis. When system \(x_{c} \cdot \text{GSH-GPX4} \) is inhibited, obstruction of the cystine transport pathway can decrease GSH and GPX4, which can lead to cell death due to ongoing oxidative stress (Figure 1A).

In relation to obesity, genetic variants in GPX4 have been linked to obesity and inflammation in humans (38, 39), suggesting a role for GPX4 in metabolic disorders. And studies have described that impaired GPX4 activity is associated with obesity, although the biological consequences have not yet been determined (32). It is certain that obesity leads to the expansion of adipocytes, causing an inadequate supply of oxygen within AT and promoting the secretion of pro-inflammatory cytokines and ROS (40–42). The presence of the antioxidant GPX4 has also been shown to neutralize the ROS produced by the oxidative stress of AT and control AT inflammation by preventing lipid peroxidation (43). Furthermore, the same study also revealed that the activity of adipocytes GPX4 in obese patients is reduced, but the consequences seem to more of effect on undifferentiated adipocytes, but not as obvious for mature adipocytes (32, 43, 44). As a substance necessary for adipocytes differentiation, the reduction in GPX4 may affect AT remodeling, which is manifested by the finding that Gpx4−/− AT mice have larger adipocytes and a considerably increased body weight compared to wild-type mice; additionally, GPX4 can inhibits the
phospholipid peroxidation of adipocytes, although the specific mechanism is unclear (43). Additionally, increased fasting blood glucose and insulin resistance were also observed in Gpx4−/− AT mice, and spontaneously produced impaired insulin signaling in the liver, resulting in systemic inflammation and disorders of glucose metabolism (43). In conclusion, there is a strong association between GPX4 and obesity, and GPX4-centered ferroptosis may be the key link between GPX4 and obesity.

FSP1

Ferroptosis-suppressor-protein 1 (FSP1) is a recently discovered non-GPX4-dependent ferroptosis inhibitory factor, which exhibits a different pathway of action from GPX4 in the process of ferroptosis inhibition, mainly regulated by the NAD (P)H/FSP1/CoQ10 system (45) (Figure 1C). As a consequence, both ultimately act on lipid radicals to reduce cellular damage caused by their excessive accumulation, and the loss of FSP1 can also increase PLOOHs. Apparently, FSP1 provides another important pathway for ferroptosis that is not limited to mitochondria (46, 47). Indeed, the sensitivity of different cancer cells to GPX4 inhibitors is highly variable, and some are unaffected by GPX4 (48). Therefore, the emergence of FSP1 may compensate for some of the shortcomings of GPX4. However, whether there is an FSP1-based pathway at play in adipocytes without ferroptosis when GPX4 is reduced requires further investigation. The available results suggest that FSP1 can play an important role in predicting the efficacy of ferroptosis-inducing drugs in cancer, and FSP1 inhibitors are considered to have great potential to overcome ferroptosis resistance.

GCH1

To identify other ways to regulate ferroptosis sensitivity, a new set of ferroptosis inhibition genes was identified by genome-wide activation library screening. As a result, a new ferroptosis inhibition axis with GTP cyclohydrolase-1 (GCH1) as the core was finally determined, which was found to be mainly regulated by the GCH1/BH4/DHFR pathway, which also protected cells from ferroptosis in a GPX4-independent manner (49, 50) (Figure 1D). However, studies only point to the key role of BH4 in protecting cells when GPX4 is inhibited, and its influence on lipid peroxidation is unrelated to its cofactors, but the specific mechanism remains unclear (50). Currently, the GCH1-based ferroptosis inhibition pathway only focuses on the therapeutic feasibility of tumors and cancer cells, with no obesity-related studies as of yet (49). However, as a polymorphism site for human and chronic diseases, including diabetes and hypertension, GCH1 can play a role in adipocytes and their related regulatory pathways.

SLC7A11 (xCT)

With the deepening of ferroptosis research, studies have strengthened the strategy of using the Cystine/Glutamate reverse transporter SLC7A11 (xCT) pathway to regulate ferroptosis, the principle of which is also based on the antioxidant axis system xCT−GSH-GPX4, but the focus falls on the key precursor system of the system xCT− (51). The system xCT− is actually a sodium-independent antiporter, consisting of the heavy chain subunit solute carrier family 3 member 2 (SLC3A2) and the light chain subunit SLC7A11 (52, 53). SLC3A2 can anchor SLC7A11 to the plasma membrane and maintain the stability of its protein (54), while SLC7A11 can mediate the activity of the reverse transporter of system xCT− (55, 56) (Figure 1B). The two work together to transfer extracellular cystine and intracellular glutamate out in a 1:1 ratio, thereby driving the efficient operation of the GPX4 antioxidant axis and protecting cells from oxidative stress damage (57, 58).

However, because the function of SLC3A2 is not limited to cystine transport pathways, studies mainly focus on regulating SLC7A11 to inhibit the ferroptosis resistance of cancer cells (56). In addition, the activity and expression of SLC7A11 is strictly regulated by multiple mechanisms, such as transcription factor 4 (ATF4), nuclear factor erythroid 2–related factor 2 (NRF2), ubiquitin BRCA1 (Breast cancer gene 1)-associated protein-1 (BAP1), the SWI/SNF complex, and rapamycin complex 1 (mTORC1) (51), through which the expression of SLC7A11 can be upregulated to enhance the antioxidant defense of cells and inhibit the occurrence of ferroptosis (Figure 1B).

In general, there are four main mechanisms, GPX4, FSP1, GCH1 and SLC7A11, to help the body resist oxidative stress. Their operation is also precisely controlled by many regulators, but even under the conditions of so many pathways, more and more studies still regard SLC7A11 as the rate-limiting precursors and GPX4 as the core antioxidant defense to against ferroptosis (8).

Association between obesity and ferroptosis

Studies found that obesity is closely related to iron metabolism disorders, which are mainly reflected as an excessive iron level (59). Ferroptosis caused by iron accumulation is accompanied by elevated ROS and inflammatory response, insulin resistance and mitochondrial dysfunction, leading to metabolic disorders and the development of obesity (60). As a result, the link between obesity and ferroptosis in different aspects has gradually become clear. At the iron level, a previous study found that iron accumulation occurred in the epididymal adipose tissue (eAT) of polygenic obese and diabetic mice, but did not occur in the subcutaneous and brown adipose tissue (61). The available data are sufficient to show that iron accumulation is more obvious in the pancreas, liver, and heart, all of which are traditional tissues with excessive iron. Adipose tissue (AT) iron overload is also closely related to macrophages, mainly reflected in the important role of macrophages in controlling iron metabolism (62). Studies have shown that obesity induces increased M1 macrophages (M1) polarization in mice, which may further promote iron deposition, according to in vitro studies (63). Interestingly, studies have...
identified adipose tissue macrophages (ATMs) with iron-processing phenotypes, noting that a high-fat diet (HFD) promotes iron entry into adipocytes and inhibits the ability of ATMs to process iron (64). These studies also further illustrate the role of ATMs in the connection between iron and adipocytes. In addition, another study in mice with high-speed rail diet intervention also yielded an interesting result, showing that eAT produced robust remodeling, which was accompanied by AT weight reduction and a significant increase in iron content. This further suggests that processes associated with ferroptosis may play roles in AT remodeling (61). In a word, these findings further embody the relevant metabolic regulatory network in complex biological systems, with ferroptosis and obesity caused by iron accumulation as the connection point, and the parallel occurrence of the inflammatory response and insulin resistance.

Under an inflammatory environment and oxidative stress, as obesity progresses, the increased secretion of pro-inflammatory cytokines and chemokines, such as monocyte chemotactic, tumor necrosis factor (TNF) α, and interleukin (IL)-6, lead to a low-grade inflammatory response throughout the body (65). This is similar to the environmental changes that accompany ferroptosis. Moreover, the increased iron is also accompanied by oxidative stress in the pancreas, liver, and eAT. In polygenic obese mice, iron chelating agents inhibit inflammatory factors and the production of oxidative stress, as well as the infiltration of ATMs to improve the hypertrophy of adipocytes (66, 67), which further indicates that ferroptosis may occur in AT. Indeed, the development of obesity and ferroptosis indicates the weakening of the body’s antioxidant capacity, which in turn leads to a series of metabolic disorders.

Regarding insulin resistance, studies have shown that omental adipocytes size and insulin resistance are positively correlated, and long-term obesity induces systemic inflammation and insulin resistance (68, 69). Moreover, an increase in inflammatory factors and a decrease in adiponectin may also lead to the interruption of insulin signaling pathways, reducing insulin sensitivity (70, 71). An increase in iron storage also causes insulin resistance, and insulin sensitivity increases after reducing serum iron levels. During insulin therapy, iron uptake can be increased by increasing the transferrin receptor 1 (TIR1) in adipocytes (72).

Regarding mitochondrial function, obesity can lead to mitochondrial dysfunction, an abnormality that mostly occurs in the liver, muscles, and AT that are associated with high energy, nutrient, and lipid overload (73). Furthermore, the morphology and number of mitochondria in obese patients have also changed. For example, the mitochondria in their skeletal muscle have become smaller and shorter, while those of white adipose tissue (WAT) are small and elongated, with an irregular crest, and the larger the adipocytes, the less mitochondria are present (74–76). Additionally, mitochondrial dysfunction in AT under obese conditions can significantly increase respiration and biogenesis, promote fatty acid oxidation and alter metabolism, all of which lead to the production of excess acetyl-CoA (77, 78). This is due to the fact that obesity enhances the production of ROS in mitochondrial, which can damage the lipid membranes, proteins, and enzymes of the respiratory chain in the mitochondria, as well as DNA (77). In summary, obesity leads to decreased mitochondrial function and increased insulin resistance. It is thought that there is a close link between the two given the known mitochondrial dysfunction caused by iron accumulation in adipocytes.

The special link between adipocytes and ferroptosis. Although there are substances, genes, and environmental changes within AT that are required for ferroptosis. However, there seems to be a contradictory result between adipocytes and ferroptosis, as shown by the proliferation of adipocytes despite being under ferroptosis conditions (79). Therefore, to demonstrate whether adipocytes can undergo apoptosis in response to oxidative stress, one study treated mature adipocytes with H2O2 and found that an increase in ROS enhanced adipocyte apoptosis (80). These results suggest that not only AT remodeling but also differentiated adipocytes can still be affected by ferroptosis. So how do adipocytes in AT defend against ferroptosis? One speculation is that although adipocytes have reduced GPX4, adipocytes may be similar to some tumor cells, which still have a high level of GSH in their cells, so that although adipocytes are in an overall oxidative stress condition, the remaining GPX4 from GSH is still needed to neutralize large amounts of ROS and remove some of the lipid peroxides, resulting in differentiated adipocytes that are not or less affected by ferroptosis (81). Compared to the former speculation, another study found that adipocytes can secrete specific fatty acids to induce ferroptosis resistance in breast cancer cells, and this process was dependent on the fatty acid synthetase ACSL3, confirming that breast cancer cells co-cultured with peri-tumor adipocytes showed resistance to ferroptosis (82). In addition, the team verified the protection of adipocytes against ferroptosis in triple-negative breast cancer through animal models. These results provide a new idea as to why adipocytes in obese AT do not undergo ferroptosis and continue to proliferate.

In conclusion, on the basis of these studies, this review speculated that there may be two mechanisms of ferroptosis leading to obesity: (i) In the autonomic nervous system, vagus and parasympathetic nerves in some organs or tissues may be affected by ferroptosis and become dysfunctional, while the inflammatory factors released from adipocytes lead to excessive sympathetic activation and hypothalamic neuronal ferroptosis which promotes the development of obesity through a series of processes; (ii) Ferroptosis may have occurred in certain anti-inflammatory immune cells in AT, which allows a large increase in pro-inflammatory immune cells, further causing systemic inflammation and insulin resistance, and ultimately leading to the development of obesity. Unfortunately, although ferroptosis, a novel mode of cell death, has received widespread attention from researchers since its discovery, there are still few studies on AT related to ferroptosis. Most of the studies are still mainly focused on tumor cells (30), and a certain theoretical system has not yet been formed, resulting in many specific mechanisms related to it are not very clear.
At present, the rapidly rising prevalence of obesity has become a global problem that needs to be solved. The discovery that AT can be affected by the process of ferroptosis provides us with another idea to treat obesity. Therefore, this review will investigate whether the neurological and immune systems can regulate the ferroptosis process in AT. Finding out the role of ferroptosis in AT, and thus provide a new therapeutic target for the treatment of obesity, which is important for the clinical treatment of human obesity.

Neuromodulation of obesity and ferroptosis

The nervous system is known to play a leading role in the regulation of physiological functional activities, but is also closely related to AT as a result of the dynamic crosstalk between adipocytes and other types of cells in the highly neurologically innervated and vascularized tissue matrix (83). Therefore, a large number of studies in recent years have actively explored the innervation of AT, and the results have confirmed the presence of only sensory innervation and sympathetic innervation within AT (83). Among them, the fat sensory nerve will convey the metabolic signal in AT to the central nervous system, and then instruct AT through the sympathetic nerve (84–86), so that it can carry out the corresponding lipolysis and thermogenesis according to the instruction (87, 88) (Figure 2). However, under obese conditions, the number of nerve fibers within the AT appears to be drastically reduced, which not only leads one to ponder whether there is some association with ferroptosis. Besides, the exact mechanism leading to the reduction of nerve fibers remains unclear. What is known is that the expansion of adipocytes causes tissue inflammation and diminished sympathetic signaling (83, 89). This leads to dysregulation of sympathetic neurotransmitter levels of NPY, ATP and NE, resulting in a chronic over-activation of sympathetic nerves, but with reduced sensitivity of β-adrenergic receptors, resulting in a weakened regulation of AT and a proliferation of adipocytes. Moreover, cytokines released from adipocytes such as leptin stimulate AT sensory nerve fibers and may lead to their hyperactivation and release of inflammatory factors, further inflammatory stimulation and oxidative stress may inhibit normal hypothalamic and nervous system function (89–91). In addition to the innervation within the AT, the autonomic nervous system is known to populate all organs and tissues of the body. As a whole, there is also a network of alternating influences between these autonomic nervous systems and the AT. For example, in the vagus nerve, although postganglionic neurons...
of the vagus nerve may be located outside of AT, studies have found that some preganglionic axons of the vagus nerve terminate on neurons of unknown phenotype in the adrenal, celiac, and superior mesenteric ganglia. Since neurons in these ganglia may contribute to sympathetic innervation of at least the intraperitoneal AT, this could also be a potential pathway for vagal innervation. Not only that, but studies have found ferroptosis in the nervous system (92). The reason may be related to the high activity of brain nerves. The high metabolic rate and high oxygen consumption of brain parenchyma will inevitably lead to the production of a large number of by-products ROS, and may further cause oxidative stress (93). At the same time, the brain is relatively limited in antioxidant factors, but it is also rich in iron, which can react with endogenous H$_2$O$_2$ to promote lipid peroxidation (94). And membranes with high PUFA-PL content should be particularly susceptible to peroxidation, as has been demonstrated in neurons (93). In addition to this, the iron accumulation seen in the liver of obese patients is an interesting echo of hepatic parasympathetic dysfunction. In conclusion, the systemic inflammation induced by obesity may accelerate the process of ferroptosis in certain neuronal cells, and this could potentially further promote the development of obesity (95).

**Vagus nerve**

The vagus nerve is the main nerve of the parasympathetic branch (96), which can participate in taste sensation and innervate most organs, including the liver, stomach, and pancreas, and regulate circulation, breathing, and digestion by conducting sensory impulses in organs, particularly those controlling the activity of the heart muscle, glands, and smooth muscles (97, 98). In terms of the relationship with obesity, studies have found that in obese humans and rodent models, autonomic imbalances include excessive activation of the vagus nerve (99, 100), and a decrease in the mass of WAT is induced after vagus nerve resection (100). However, this idea, while demonstrating the ameliorative effect of vagus nerve excision on the association with obesity (101), is limited by the absence of significant changes in some lean animals and some populations (98), as well as the increased occurrence of secondary trauma and mortality after excision (102). As an important component of regulating metabolism and immune homeostasis, the vagus nerve can regulate SAT content through the central nervous system to control sympathetic peripheral muscle bundles, and can also regulate the release of GSH and NO to enhance antioxidant capacity and prevent ferroptosis (36). Thus, the vagus nerve may be involved in maintaining oxidative homeostasis and responding to external stimuli or injury. For example, in acute respiratory distress, ferroptosis has been found in mouse lung tissue, together with iron accumulation, increased ROS, and lipid peroxidation (103). The use of electro-acupuncture to stimulate the Zusanli (ST36) acupoint can activate the α7 nicotinic acetylcholine receptor in the lung tissue through the cervical vagus nerve and sciatic nerve to protect the ferroptosis in the lung tissue, which also verifies the importance of the vagus nerve in protecting the oxidative damage of cells (104) (Figure 2). The vagus nerve can also inhibit the release of pro-inflammatory cytokines in such a way that mediates selective cholinergic activation in the inflammatory response, thereby improving inflammation and obesity (97, 98, 105). Surprisingly, the emergence of obesity seems to break the protective ability of the vagus nerve, not only the oxidative damage of organs and tissues (i.e., the liver and pancreas), but also in terms of transmission signal interruption and decreased plasticity (98) (Figure 2). Indeed, some studies have pointed out that this phenomenon may be an important mechanism for developing obesity (106). Overall, autonomic imbalances caused by obesity may be associated with the first occurrence of ferroptosis in the vagus nerve, which impairs its ability to transmit information collected by the sensory nerve to the nerve center, as well as its ability to mobilize GSH and NO to prevent ferroptosis.

**Parasympathetic nerve**

As another major component of the autonomic nervous system that neutralizes sympathetic activity, and has a complete mediated pathway to the pancreas, the parasympathetic nervous system plays an important role in maintaining metabolic homeostasis, such as maintaining blood sugar (107). Parasympathetic efferent nerves can transmit neuropeptides and acetylcholine to the islet liver, increasing insulin release and liver NO production through muscarinic receptors and lowering blood sugar. In addition, despite a lack of evidence of the parasympathetic innervation of WAT (108, 109), it can still affect WAT through multiple pathways, and studies have suggested that reduced parasympathetic activity is associated with obesity (110). Correspondingly, the link between parasympathetic injury and ferroptosis has gradually become clear. Diabetes mellitus, which is a complication of obesity, can activate satellite glial cells of the supraventricular ganglia through P2Y receptors, resulting in increased expression of pro-inflammatory cytokines such as IL-1β, and causing oxidative damage to the autonomic nerves such as via an inflammatory response (111, 112) (Figure 2). Among them, oxidative damage to the autonomic nervous system due to iron accumulation associated with diabetes may be due to changes in the NRF2-GPX4 pathway in ferroptosis (113, 114), the transcription factor that regulates SLC7A11 (51) can effectively prevent oxidative damage in various pathological conditions upon NRF2 activation (115, 116). Furthermore, both obesity and diabetes are accompanied by significant increases in ROS and decreases in NRF2 and GPX4 levels, indicating a weakening of antioxidant capacity and activation of the ferroptosis process. Simultaneously, ferroptosis may be involved in the progression of cardiac autonomic neuropathy (DCAN) through the P2Y14 receptor (a new member of the metabolic...
receptor family), while P2Y14 targeting naringin can alleviate DCAN by promoting the NRF2-GPX4 pathway to eliminate ROS and inhibit ferroptosis (117) (Figure 2). Surprisingly, another study showed that diabetes-related cardiovascular autonomic damage is first manifested in the vagus nerve (106), which may involve a ferroptosis-mediated overall decrease in parasympathetic tone, ultimately leading to over-activation of the sympathetic nerve and the worsening development of metabolic complications. In conclusion, these studies elucidate the role of obesity and diabetes in promoting autonomic nervous system imbalances and metabolic disorders through the ferroptosis process (106).

**Sympathetic nerve**

The sympathetic nervous system plays a key role in regulating metabolic control as an important hub that connects the brain to most organs, glands, and tissues, including the heart. Particularly in regulating AT, which is only innervated by the sympathetic nerves, while the liver, skeletal muscle, and pancreas are under the control of the parasympathetic nervous system (118). Studies have shown that sympathetic hyperactivation is strongly associated with hyperinsulinemia, impaired baroreceptors, angiotensin II, apnea syndrome, and adipokines (119). Furthermore, studies have highlighted that ROS can activate the sympathetic nervous system (120), suggesting that the sympathetic nervous system may be less inhibited under high oxidative stress. However, it has also been shown that sympathetic neurons undergo lipid peroxidation following cleavage of the p75 neurotrophic factor receptor, causing degeneration and cell death (121). Considered another way, sympathetic hyperactivation indicates that the inhibitory effects of the vagus and parasympathetic nerves have weakened, which may also be an important mechanism for developing obesity. In obese conditions, the vagus and parasympathetic nerves may be damaged due to ferroptosis, which also promotes further sympathetic activity and autonomic nervous system imbalance. Furthermore, studies have found that antioxidants can reverse sympathetic dysfunction, oxidative stress, and hypertension in male obese rats following intervention with antioxidants (122). It has also been shown that impaired baroreceptor reflexes are caused by reduced inhibition of the vagus and parasympathetic nerves (123). In conclusion, these data show that the overactivation of the sympathetic nerve under obese conditions is closely related to ferroptosis of the vagus nerve and the parasympathetic nervous system. Additionally, the sympathetic nervous system may have a complex mechanism that inhibits the effects of oxidative stress represented by ferroptosis.

**AgRP and POMC neurons**

In addition to the vegetative nervous system described above, traces of ferroptosis have been found in neurons in some specific areas associated with obesity. For example, HFD has increased secretion of free fatty acids and pro-inflammatory cytokines. When these pro-inflammatory mediators reach the hypothalamus, they increased the levels of oxidative stress and neuronal inflammation in the hypothalamus through processes such as microglia proliferation (124, 125). Insufficient GSH, the only antioxidant in the hypothalamus, may cause ferroptosis in some neurons, leading to further metabolic disorders. Leptin-activated hypothalamic proopiomelanocortin (POMC) and agouti-related protein (AgRP) neurons located in the arcuate nucleus are typical (126, 127). The former increases appetite and the latter suppresses appetite, both of which are critical for the metabolic homeostasis of the body (128). Studies have shown that a high-fat, high-sucrose (HFHS) diet decreased GPX4 expression and activity in the hypothalamus of mice associated with elevated GPX4 levels in WAT (129). Surprisingly, the decrease in GPX4 failed to damage the integrity of both neurons, and mice that only lost GPX4 in AgRP neurons experienced weight gain, while POMC neurons required for ROS buffering and metabolic homeostasis were unaffected by GPX4 deletion (129) (Figure 2). This phenomenon is indeed elusive, but it is speculated that there may be other antioxidant pathways that inhibit this process. In contrast, another study that specifically induced the death of AgRP and POMC neurons, profound metabolic disorders and obesity emerged (129) (Figure 2). In summary, although the two neurons did not die of GPX4 reduction, the study focused on only one point of GPX4 and did not delve into other regulators, indicating that there are other pathways affecting the activity of POMC neurons under obesity conditions (129). However, this phenomenon also confirms that the increase in high levels of plasma under previous obesity conditions can cause POMC neuron stimulation, which will further induce sympathetic activation. Additionally, these studies continue to demonstrate that GPX4 deletion can cause oxidative damage to membranes and exacerbate neuroinflammation. Therefore, improving obesity by improving oxidative stress caused by ferroptosis in the hypothalamus and nervous system is an essential consideration.

**Immunomodulation with obesity and ferroptosis**

With the continuous in-depth study of obesity, the importance of AT immune cells as a key hub for regulating the AT environment has become recognized. AT immune cells not only promote AT homeostasis, but also change phenotype and increase their number to promote the maintenance and development of local AT inflammation. AT immune cells also secrete pro-inflammatory cytokines and other pro-inflammatory products into the systemic circulation, which affect the entire body, thus representing a key factor in the transition from simple obesity to cardiovascular disease, type II diabetes, and related metabolic disorder complications (130). It should be clarified that although the contribution of immune cells to metabolic diseases is mainly...
concentrated in AT, an effective source of such inflammation also exists in the liver, intestines, and other metabolic regulatory tissues, promoting the production of inflammation and obesity throughout the body through the circulation (131). In addition, AT remains the most commonly studied source of immune-mediated inflammation in obesity. In the case of eWAT, an increase in endogenous fatty acids following adherence to a HFD activates two sensors within adipocytes, Toll-like receptor 4 (TLR4) and inflammasomes, which causes an influx of neutrophils to enter the eWAT, leading to increased levels of chemokine and cytokine expression (132). Among them, the most typical is the chemokine Leukotriene B4 (LTB4), the increased expression of which causes recruitment of neutrophils, ATMs, T cells, and B cells, which increase expression of pro-inflammatory cytokines, eventually leading to the development of eWAT inflammation and obesity (132) (Figure 3). Therefore, in response to iron accumulation and high levels of ROS within AT, certain anti-inflammatory immune cells may also be affected by the ferroptosis process, resulting in their inability to neutralize the inflammatory response caused by pro-inflammatory cytokines in a timely manner. Currently, known immune cells present within AT include ATMs, T cells (CD4+, CD8+, Tregs), natural killer T cells, B cells, neutrophils, eosinophils, and dendritic and mast cells (130, 133, 134). Based on current research progress and the association of these immune cells with obesity and oxidative stress, this review identified macrophages, T cells, B cells, and neutrophils, which are closely related to oxidative stress and metabolic disorders, and sorted out their changes in obesity and these immune cells complication-related pathways to identify ferroptosis traces.

**Macrophages**

ATMs are central players in obesity-related inflammatory and metabolic diseases and can be involved in the regulation of adipocytes energy metabolism and mitochondrial function (133), thereby promoting post-inflammatory or post-injury

---

**FIGURE 3**

Immunoregulation of obesity and ferroptosis. In the early stages of obesity, HFD stimulates TLR4, a sensor within VAT, and inflammatory vesicles to release certain signals to promote neutrophil entry into VAT, followed by the release of chemokines (LTB4) by neutrophils to further promote the aggregation of ATMs, T cells, and B cells in VAT. Simultaneously, their pro-inflammatory phenotype releases numerous pro-inflammatory cytokines, which increases the levels of ROS, iron, pro-inflammatory cytokines, adipocyte-secreted chemokines, and leads to increased inflammation due to ferroptosis in some types of anti-inflammatory immune cells. ATMs: obesity impairs the iron reserve capacity of M1 macrophages and promotes their polarization toward the M1 phenotype. At the same time, a large number of pro-inflammatory cytokines also inhibit the upregulation of the NRF2 gene and GSH levels through glucose metabolism and the pentose phosphate pathway in M2 macrophages, which have antioxidant capacity, resulting in reduced GPX4 levels and ferroptosis in M2 macrophages. T cells: obesity causes T cells to release IFN-γ and CD40-CD40L to promote M1 and B2 production. Tregs undergo ferroptosis due to reduced levels of NRF2, GPX4, and GCH1. B cells: obesity promotes the entry of B cells into VAT via the LTB4R1 receptor, whereas B1 cells may also undergo ferroptosis due to reduced GPX4. Neutrophils: neutrophils activate the CaMKIV/CREM axis to induce apoptosis spontaneously, which may involve ferroptosis-related processes.
repair, as well as tissue remodeling (135). ATMs have two main phenotypes: M1 macrophages (M1) is considered the culprit of AT inflammation, can participate in glycolysis to rapidly produce ATP, and plays a key role in the initiation and maintenance of systemic inflammation and insulin resistance; and M2 macrophages (M2) uses the effective coupling of respiration in the electron transport chain to enhance oxidative phosphorylation (OXPHOS), reduces ROS production, and promotes improved obesity and systemic glucose homeostasis by inhibiting adipocytes proliferation (136, 137). Additionally, studies have identified two new ATMs that are closely related to iron metabolism and oxidative stress: iron-rich ATMs (MFε+ω) and antioxidant ATMs (Mox) (138). Impaired MFε+ω affects iron distribution, leading to AT dysfunction and adipocyte iron overload in obese patients; Mox inhibits oxidative damage by upregulating NRF2-dependent antioxidant enzymes and producing GSH, which has been shown to be the main ATMs for lean AT (64, 138).

At present, the interaction between ATMs and ferroptosis is gradually becoming clear, studies have shown that ATMs secrete IL-6, TNF-α, IL-1β, and iNOS, which can induce or inhibit the process of ferroptosis through different routes (139–142). Notably, IL-6 not only modulates hepcidin to affect the release of stored iron from ATMs and intestinal absorption, but also reduces transferrin expression, does the in...
As effector cells that produce specific antibodies, B cells can be mainly divided into B1 and B2 cells; among which, B2 cells have a pro-inflammatory effect. In an obese environment, many B2 cells are recruited into VAT through the action of the chemokine leukotriene B4 (LTB4) and its receptor LTB4R1, leading to tissue inflammation and the development of insulin resistance (163) (Figure 3). For B1 cells, B-1b cell subsets and the anti-inflammatory IgM natural antibodies alleviate dietary glucose intolerance and obesity metabolic dysfunction (164). However, among the pro-inflammatory and anti-inflammatory B cells, obesity is largely characterized by B2 cell accumulation and B1 cell damage within VAT (163, 165). Interestingly, GPX4 prevents ferroptosis due to lipid peroxidation in B1 cells, but is optional for maintenance and development in B2 cells (166). Therefore, it is important to determine whether the high concentration of ROS and the decline in antioxidant capacity caused by obesity causes ferroptosis in B1 cells. This is currently uncertain, with many unexplained mechanisms between AT, GPX4, and immune cells. It is certain that while B1 cells from the spleen did not die of iron during GPX4 deficiency, B1 cells taken from the abdominal cavity of mice experienced a higher degree of ferroptosis at the time of GPX4 defect (166) (Figure 3). It is worth pondering whether B1 cells in the obesity eAT will also undergo similar changes.

Neutrophils

New research data suggest that neutrophils are also involved in the development of AT inflammation and insulin resistance, for instance, by infiltrating AT early in obesity and producing chemokines and cytokines that promote ATM infiltration (167). Neutrophil-derived proteolytic enzymes (i.e., myeloperoxidase and elastase) may also be involved in the initiation of AT inflammation (132). On this basis, some studies have indicated that an HFD caused by the NF-kB pathway increases the specific expression of IL-1b in eWAT neutrophils, which far exceeds the contribution of ATMs (132). Taken together, these results support the idea that neutrophils penetrate AT, causing high numbers of ATMs and IL-1b levels to drive obesity and insulin resistance (132). Surprisingly, to prevent activated neutrophils from releasing their highly cytotoxic inflammatory mediators into the tissue environment and damaging surrounding tissues along the bloodstream, neutrophils spontaneously undergo apoptosis. Although the mechanism that triggers this apoptosis remains unclear, the apoptosis process plays a key role in maintaining immune homeostasis and eliminating inflammation (168). Furthermore, neutrophil apoptosis is accompanied by a lack of GSH, and GSH may play an important role in this apoptosis process. Correspondingly, treatment with exogenous GSH and LPS was found to delay apoptosis and reduce the level of the pro-apoptotic protein caspase-3 (169). Although the relevant data do not prove the effect of ferroptosis in this process, the effect of GSH infers an association with ferroptosis. Therefore, to explore whether there is an association between neutrophils and ferroptosis, another study explored the role of GPX4 in neutrophil ferroptosis and identified two key factors, namely serum autoantibodies and IFN-α (170), both of which induce iron apoptosis in neutrophils by activating the CaMKIV/CREMα axis, leading to SLE neutropenia. An increase in the nuclear translocation of CaMKIV/CREMα decreases GPX4, which is accompanied by an increase in intracellular lipid-ROS, eventually leading to neutrophil iron apoptosis (170) (Figure 3). Although the focus of the study was on systemic lupus erythematosus, the data demonstrate that ferroptosis can occur in neutrophils (170). Overall, these data suggest a strong link between neutrophils and ferroptosis. The accumulation of many neutrophils in obese AT shows that neutrophils are unaffected by ferroptosis, which may be similar to other pro-inflammatory immune cells. However, the role of neutrophil ferroptosis in immunodeficient diseases is worth considering, particularly whether there are shared pathways that mediate the process of ferroptosis.

Conclusions and outlook

This review summarizes the characteristics of iron metabolism in humans, the association between obesity and ferroptosis, and the neuroimmune regulation associated with obesity and ferroptosis. While many of these mechanisms are still unknown, there is growing evidence that ferroptosis plays a key role in obesity and its complications, including type II diabetes, hypertension, nonalcoholic steatohepatitis, atherosclerosis, and obese cardiomyopathy (171). Moreover, ferroptosis may not only play a direct role in AT, but also indirectly promote the development of obesity through the inflammatory response and insulin resistance caused by liver autonomic and immunomodulatory disorders (Figure 4). Indeed, ferroptosis occurs through the intersection of multiple pathways to form an intricate regulatory network with obesity, so that one or more cells in the AT ferroptosis has the potential to change the fate of the entire tissue development. Therefore, research related to obesity with different ferroptosis targets is constantly emerging, and its specific mechanisms are gradually becoming clear. In addition to this, research into cuproptosis, which is similar to ferroptosis, has also appeared in recent years. As the name suggests, this is a form of cell death caused by copper, in which copper ions directly bind to protein lipoylation components in the tricarboxylic acid circulation pathway, causing abnormal aggregation of lipoylated proteins and loss of iron-sulfur cluster protein, resulting in protein toxic stress responses and cell death (172). Interestingly, the cuproptosis approach to cell death caused by the tricarboxylic acid cycle is similar to ferroptosis, in that ferroptosis also involves mitochondrial dysfunction and the production of excess acetyl-CoA. Thus, it is worth exploring whether the development of cuproptosis is indirectly related to ferroptosis. Ultimately, the current research on both ferroptosis and cuproptosis is still in its infancy, and it is not yet possible to confirm their specific mechanisms. However, the
performance of nerve and immune cells involved in their action process still proposes novel therapeutic targets for obesity and related metabolic diseases, as well as cancer. With the continuation of research, the mechanism of ferroptosis and obesity metabolic disorders will likely be deciphered in the near future, opening up the option to reasonably mediate cellular ferroptosis through accurate scientific targets for treating obesity.

Author contributions

SZ read the literature related to the topic and participated in drafting the manuscript. ZS, XJ and ZL participated in searching and archiving the literature related to the topic and discussed the contents of the manuscript. LD, CL, QW and XT revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the Taishan Scholars Program of Shandong Province (tsqn201909148), the central government guides local science and technology development funds (YDZX2022091), and the technology research and integrated application of scientific fitness smart chip and cloud service platform(2020CXGC010902).

Acknowledgments

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Linking immunity and metabolism.

Glutathione production and transformation.

Stimulation alleviates hepatic ischemia and reperfusion injury by regulating mediated inhibition of ferroptosis.

Oxidative stress as an underlying contributor in the development of chronic chemokine CCL2 secretion.

Diaz AG, Cardona-Munoz EG. Diabetic polyneuropathy in type 2 diabetes.

Oxidative and inflammatory response predominantly through a TLR2-syk-ceramide inflammation through a TLR2-syk-ceramide inflammatory response.

Vagus nerve and postprandial insulin resistance that involves parasympathetic function.

Vagus nerve and disease.

Vagus nerve and melanocortins.

Vagal innervation and immunohistochemical evidence of parasympathetic innervation of the vagus nerve involvement.

Central orchestration of peripheral nutrient partitioning and substrate utilization: Central organization of peripheral nutrient partitioning and substrate utilization.

And melanocortins.

Activation of hypothalamic melanocortin neurons in obesity, type 2 diabetes mellitus and cardiovascular diseases.

Activation of hypothalamic melanocortin neurons in obesity, type 2 diabetes mellitus and cardiovascular diseases.

Brain Res Brain Res Rev (2005) 48:457–76. doi: 10.1016/j.brainresrev.2004.09.001

Brain Res Brain Res Rev (2010) 64:304–32. doi: 10.1016/j.brainresrev.2010.04.009

Brain Res Brain Res Rev (2015) 80:158–74. doi: 10.1016/j.brainresrev.2015.01.015

Brain Res Brain Res Rev (2019) 104:150–9. doi: 10.1016/j.brainresrev.2019.03.004

Brain Res Brain Res Rev (2012) 69:1–15. doi: 10.1016/j.brainresrev.2012.03.001

Brain Res Brain Res Rev (2007) 54:1–27. doi: 10.1016/j.brainresrev.2006.12.003

Brain Res Brain Res Rev (2004) 46:29–42. doi: 10.1016/j.brainresrev.2004.06.001

Brain Res Brain Res Rev (2003) 41:109–21. doi: 10.1016/S0165-0173(03)00219-0

Brain Res Brain Res Rev (2001) 36:1–24. doi: 10.1016/S0165-0173(01)00151-5

Brain Res Brain Res Rev (1999) 30:1–16. doi: 10.1016/S0165-0173(99)00110-x
immunometabolism.

143. Jung HS, Shimizu-Alberinge M, Shen X, Kramer F, Shao D, Vivekanandan-Giri A, et al. TNF-alpha induces acyl-CoA synthetase 3 to promote lipid droplet formation in human endothelial cells. J Lipid Res (2021) 60:31–44. doi: 10.1194/jlr.RA11900256

144. Wen Y, Chen H, Zhang L, Wu M, Zhang F, Yang D, et al. Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triple-negative breast cancer cells. Free Radic Biol Med (2017) 103:6425–40. doi: 10.1016/j.freeradbiomed.2017.07.019

145. Yuan Y, Murakami M, Sugiyma M, Hashimoto O, Matsui T, Funab M. Hepcidin and IL-1beta. Vitam Horm (2019) 103:143–56. doi: 10.1016/bs.vh.2019.01.007

146. Zhang B, Yang Y, Yi J, Zhao Z, Ye R. Hyperglycemia modulates M1/M2 macrophage polarization in a diabetic condition. J Cell Physiol (2018) 233:6425–40. doi: 10.1002/jcp.26429

147. Zhang et al. Cardiorespiratory disease.

148. Piattini F, Matsushita M, Muri J, Bretscher P, Feng X, Freigang S, et al. Mitochondrial ROS-oxidases and iNOS, and depriving glutathione in triple-negative breast cancer cells. Induced lysosomal dysfunction impairs autophagic flux and contributes to M1 macrophage polarization in a diabetic condition. Clin Sci (Lond) (2019) 137:1759–77. doi: 10.1042/CS20190672

149. Zhou H, Liu F. Regulation, communication, and functional roles of adipose tissue B2 cells require Gpx4 to prevent lipid peroxidation and ferroptosis. Proc Natl Acad Sci U S A. (2022) 119:12596–602. doi: 10.1073/pnas.2211480119

150. Zhang Q, Wu H. T Cells in adipose tissue: Critical players in immunometabolism. Front Immunol (2018) 9:1539179. doi: 10.3389/fimmu.2018.01539

151. Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease. Br J Pharmacol (2017) 174:594–501. doi: 10.1111/bph.13705

152. Wang Q, Wang Y, Xu D. The roles of T cells in obese adipose tissue inflammation. Adipocyte (2018) 7:743–53. doi: 10.1002/adip.123945.2018165314

153. Feurer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 15:930–9. doi: 10.1038/nm.2002

154. Dorneles GP, da Silva I, Boeira MC, Valentini D, Fonseca SG, Dal Lago P, et al. Cardiorenalphysiological fitness modulates the proportions of monocytes and T helper subsets in lean and obese people. Scand J Med Sci Sports (2019) 29:1755–65. doi: 10.1111/sms.13556

155. Xu C, Sun S, Johnson T, Qi R, Zhang Z, Zhang J, et al. The glutathione peroxide Gpx4 prevents lipid peroxidation and ferroptosis to sustain T cell activation and suppression of antitumor immunity. Cell Rep (2021) 35:109235. doi: 10.1016/j.celrep.2021.109235